替诺福韦酯治疗多药耐药慢性乙型肝炎的疗效观察  

Efficacy of tenofovir dipivoxil in the treatment of multidrug-resistant chronic

作　　者：邱梅花[1] 李耿祥[1] 陈泳莲[1] 

机构地区：[1]福建省龙岩市第二医院感染科,364000

出　　处：《临床合理用药杂志》2017年第17期10-11,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察替诺福韦酯治疗多药耐药慢性乙型肝炎的临床效果。方法将医院就诊的88例多药耐药慢性乙型肝炎患者随机分为对照组和观察组,每组44例。对照组口服阿德福韦酯治疗,观察组口服替诺福韦酯治疗。观察2组患者治疗12周、24周后HBV-DNA水平下降幅度、血清生物化学和病毒应答率。结果治疗12周、24周后,观察组HBV-DNA水平下降幅度均优于对照组,差异有统计学意义(P<0.01)。观察组生物化学应答率为97.73%,高于对照组的72.73%(P<0.05);观察组病毒应答率为95.45%,高于对照组的70.45%(P<0.05)。结论在多药耐药慢性乙型肝炎患者的临床治疗中,替诺福韦酯临床效果较好,具有推广和应用价值。Objective To observe the clinical effect of tenofovir dipivoxil in the treatment of muhidrug resistant chro- nic hepatitis B. Method 88 patients suffered from muhidrug-resistant chronic hepatitis B were randomly divided into control group and observation group with 44 cases for each of the two groups. The control group was treated with oral adefovir dipivoxil and the observation treated with oral tenofovir dipivoxil. The levels of HBV-DNA decreased, serum biochemistry and virus re- sponse rate for the two groups were observed at 12 weeks and 24 weeks after treatment. Results After 12 weeks of treatment, the decrease of HBV-DNA level in the observation group was greater than that in the control group at 24 weeks （P 〈 0.01 ） ;the difference was statistically significant （P 〈0.05）. The response rate of the observation group was 97.73% ,which was higher than that of 72.73 % of the control group （P 〈 0.05）. Conclusion In the treatment of chronic hepatitis B clinical with multi- drug-resistant patients, tenofovir dipivoxil clinical effect is significant with good promotion and application value.

关 键 词：慢性乙型肝炎 多药耐药 替诺福韦酯 阿德福韦酯 HBV-DNA 应答率 

分 类 号：R512.62[医药卫生—内科学]